An analysis of gene activity profiles in lung tissue has identified important drivers of idiopathic pulmonary fibrosis (IPF). The genes discovered in this integrative analysis may predict disease outcomes and be used as potential therapeutic targets for new anti-fibrotic treatments, according to researchers. The study, “Integrative…
Since 2008, Rare Disease Day — the last day of February — has brought together patients, caregivers, family members, friends, and advocates from around the world to raise awareness and improve equity for the more than 7,000 known rare diseases that affect more than 300 million people. In 2022, the…
A novel imaging biomarker identified via an artificial intelligence (AI)-powered analysis could help predict lung function and survival outcomes for people with idiopathic pulmonary fibrosis (IPF). Brainomix, a U.K.-based software company, is developing a number of AI-based tools to analyze different diseases, including one called e-ILD…
Endeavor BioMedicines has raised $101 million to advance its pipeline programs, including taladegib (ENV-101), an investigational oral treatment for idiopathic pulmonary fibrosis (IPF) now in a clinical trial, and for cancer linked to mutations in the PTCH1 gene. The funding was the result of a series B…
The more monocyte immune cells that circulate in a person’s bloodstream, the greater the odds that lung abnormalities, such as those linked to pulmonary fibrosis, will show up on a CT imaging scan, a study found. Researchers also observed that a higher monocyte count increased the odds of lung…
Algernon Pharmaceuticals hit the full enrollment of 20 patients with idiopathic pulmonary fibrosis (IPF) in its Phase 2 study of NP-120 (ifenprodil) for persistent, hard-to-treat cough, a common symptom of the disease. Early interim data from the study (NCT04318704), underway in Australia and New Zealand, showed…
The Pulmonary Fibrosis Foundation (PFF) is welcoming pulmonary fibrosis (PF) patients, caregivers, and lung transplant recipients in the U.S. willing to volunteer as PFF Ambassadors. The PFF Ambassador program is designed to offer hope and inspiration to those affected by PF through public speaking and heightened awareness of this…
Treatment with Ofev (nintedanib) was found to prevent the progression of both cancer and idiopathic pulmonary fibrosis (IPF) in a 75-year-old woman with a history of smoking who was diagnosed with IPF and diffuse squamous cell lung cancer, a recent case study reported. Nevertheless, researchers noted that “scientific data…
Algernon Pharmaceuticals has been notified it will be given a Canadian patent, as requested, covering its investigational oral therapy NP-120 (ifenprodil) for idiopathic pulmonary fibrosis (IPF). Initially developed by Sanofi and approved for the treatment of circulatory disorders in Japan and South Korea, ifenprodil showed anti-scarring and anti-coughing effects…
Supplementary oxygen using a high‐flow nasal cannula boosts exercise endurance more effectively than standard devices in idiopathic pulmonary fibrosis (IPF) patients with suboptimal blood-oxygen levels, a small trial reported. The study, “Impact of high-flow oxygen therapy during exercise in idiopathic pulmonary fibrosis: a pilot crossover clinical trial,” was…
Get regular updates to your inbox.
